Clinical trials: Human Papilloma Virus Infection Type 16
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years ,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT03206255
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 940 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
- Conditions
- Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Type 16 Infection, Human Papillomavirus Type 18 Infection
- Trial name
- NCT06273553
- Testing
- RG002 injection
- Volunteers
- 39 people
- Sponsor
- RinuaGene Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System)…
- Trial name
- NCT07454915
- Testing
- PVX4 Combination Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 138 people
- Sponsor
- PapiVax Biotech, Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma
- Trial name
- SAVED (NCT07418034)
- Testing
- Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease
- Volunteers
- 132 people
- Sponsor
- University of Maryland, Baltimore
Cervical Cancers, Papillomavirus Infections
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
The aim of this retrospective, single-center, observational study is to improve the diagnosis and interpretation of cervical cancer by better detection of epithelial lesions in the case of a late HPV PCR amplification signal…
- Conditions
- Cervical Cancers, Papillomavirus Infections, Papillomavirus Type 16/18 Infection
- Trial name
- PaPCR (NCT06919627)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.